Cardiac xenotransplantation

Annals of Thoracic Surgery

Volumn 64, Issue 6, 1997, Pages 1858-1865

  DiSesa, Verdi J ^a  

^a ALLEGHENY UNIVERSITY HOSPITALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING; FOREIGN BODY; GENETIC ENGINEERING; GRAFT REJECTION; HEART FAILURE; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; REVIEW; XENOTRANSPLANTATION;

EID: 0031425768     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(97)00865-5     Document Type: Article

References (55)

1. Dargie HJ, McMurray JJ, McDonagh TA. Heart failure - implications of the true size of the problem. J Intern Med. 239:1996;309-315.
2. United Network for Organ Sharing, Richmond, Virginia. World Wide Web Site (www.unos.org).
3. Evans RW. Executive summary The National Cooperative Transplantation Study. BHARC-100-91-020 . 1991;Battelle Research Center, Seattle, WA.
4. Bocchi EA, Bellotti G, Noreira LF, et al. Mid-term results of heart transplantation, cardiomyoplasty, and medical treatment of refractory heart failure caused by idiopathic dilated cardiomyopathy. J Heart Lung Transplant. 15:1996;736-745.
5. Argenziano M, Oz MC, Rose EA. The continuing evolution of mechanical ventricular assist devices. Curr Probl Surg. 34:1997;317-386.
6. Li RK, Jia ZQ, Weisel RD, et al. Cardiomyocyte transplantation improves heart function. Ann Thorac Surg. 62:1996;654-660.
7. Milano CA, Allen LF, Rockman HA, et al. Enhanced myocardial function in transgenic mice overexpressing the beta 2-adrenergic receptor. Science. 264:1994;582-586.
8. Lawson JH, Platt JL. Molecular barriers to xenotransplantation. Transplantation. 62:1996;303-309.
9. Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol. 153:1994;3791-3803.
10. Galili U. Interaction of the natural anti-Gal antibody with alpha-galactosyl epitopes a major obstacle for xenotransplantation in humans . Immunol Today. 14:1993;480-482.
11. Collins BH, Cotterell AH, McCurry KR, et al. Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection. J Immunol. 154:1995;5500-5510.
12. Sandrin MS, McKenzie IF. Gal alpha (1,3) Gal, the major xenoantigen(s) recognised in pigs by human natural antibodies. Immunol Rev. 141:1994;169-190.
13. Yamada K, Sachs DH, DerSimonian H. Human anti-porcine xenogeneic T cell response. J Immunol. 155:1995;5249-5256.
14. Gress RE, Nathenson SG, Lucas PJ. Fine specificity of xenogeneic antigen recognition by human T cells. Transplantation. 48:1989;94-98.
15. Platt JL. A perspective on xenograft rejection and accommodation. Immunol Rev. 141:1994;127-149.
16. Michaels MG, McMichael JP, Brasky K, et al. Screening donors for xenotransplantation. The potential for xenozoonoses. Transplantation. 57:1994;1462-1465.
17. Michaels MG, Simmons RL. Xenotransplant-associated zoonoses. Transplantation. 57:1994;1-8.
18. Allan JS. Xenotransplantation at a crossroads prevention versus progress . Nature Med. 2:1996;18-21.
19. Ye Y, Niekrasz M, Kosanke S, et al. The pig as a potential organ donor for man. Transplantation. 57:1994;694-703.
20. Roslin MS, Tranbaugh RE, Panza A, et al. One-year monkey heart xenograft survival in cyclosporine-treated baboons. Suppression of the xenoantibody response with total-lymphoid irradiation. Transplantation. 54:1992;949-955.
21. Tanaka M, Murase N, Nomoto M, Demetris AJ, Todo S, Starzl TE. Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation inhibition of humoral response and acceptance of donor organs . Transplant Proc. 28:1996;679-680.
22. Salomon S, Steinbruchel DA, Nielsen B, Lillevang S, Kemp E. Effect of leflunomide, cyclosporine, and splenectomy in two different organ systems of concordant xenotransplantation in rats. Transplant Proc. 28:1996;698-699.
23. Fujino Y, Kawamura T, Hullett DA, Sollinger HW. Evaluation of cyclosporine, mycophenolate mofetil and brequinar sodium combination therapy on hamster-to-rat cardiac xenotransplantation. Transplantation. 57:1994;41-46.
24. Suzuki S, Nishimori H, Ohdan H, Niiya S, Amemiya H. Prolongation of cardiac xenograft survival in a hamster-to-rat combination by recipient treatment with deoxymethylspergualin. Transplantation. 56:1993;1257-1260.
25. Murase N, Starzl TE, Demetris AJ, et al. Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. Transplantation. 55:1993;701-708.
26. Hayashi S, Ito M, Yasutomi M, et al. Evidence that donor pretreatment with FK506 has a synergistic effect on graft prolongation in hamster-to-rat heart xenotransplantation. J Heart Lung Transplant. 14:1995;579-584.
27. Adachi H, Rosengard BR, Hutchins GM, et al. Effects of cyclosporine, aspirin, and cobra venom factor on discordant cardiac xenograft survival in rats. Transplant Proc. 19:1987;1145-1148.
28. Sadeghi AM, Robbins RC, Smith CR, et al. Cardiac xenograft survival in baboons treated with cyclosporine in combination with conventional immunosuppression. Transplant Proc. 19:1987;1149-1152.
29. Leventhal JR, Dalmasso AG, Cromwell JW, et al. Prolongation of cardiac xenograft survival by depletion of complement. Transplantation. 55:1993;857-866.
30. Leventhal JR, Sakiyalak P, Witson J, et al. The synergistic effect of combined antibody and complement depletion on discordant cardiac xenograft survival in nonhuman primates. Transplantation. 57:1994;974-978.
31. Mohiuddin M, Kline G, Shen Z, Ruggiero V, Rostami S, DiSesa VJ. Experiments in cardiac xenotransplantation response to intrathymic xenogeneic cells and intravenous cobra venom factor . J Thorac Cardiovasc Surg. 106:1993;632-635.
32. Hayashi S, Ito M, Yokoyama I, Takagi H. Evidence that combination therapy using cobra venom factor, splenectomy, and deoxyspergualin is effective in guinea pig to rat cardiac xenotransplantation. Transplantation. 57:1994;777-779.
33. Miyagawa S, Shirakura R, Matsumiya G, et al. Prolonging discordant xenograft survival with anticomplement reagents K76COOH and FUT175. Transplantation. 55:1993;709-713.
34. Candinas D, Lesnikoski BA, Robson SC, et al. Soluble complement receptor type 1 and cobra venom factor in discordant xenotransplantation. Transplant Proc. 28:1996;581.
35. Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation. 56:1993;1171-1176.
36. Pruitt SK, Kirk AD, Bollinger RR, et al. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts. Transplantation. 57:1994;363-370.
37. Tuso PJ, Cramer DV, Yasunaga C, Cosenza CA, Wu GD, Makowka L. Removal of natural human xenoantibodies to pig vascular endothelium by perfusion of blood through pig kidney and livers. Transplantation. 55:1993;1375-1378.
38. Cooper DKC, Ye Y, Niekrasz M, et al. Specific intravenous carbohydrate therapy. Transplantation. 56:1993;769-777.
39. Leventhal JR, John R, Fryer JP, et al. Removal of baboon and human antiporcine IgG and IgM natural antibodies by immunoadsorption. Results of in vitro and in vivo studies. Transplantation. 59:1995;294-300.
40. Sandrin MS, Fodor WL, Mouhtouris E, et al. Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med. 1:1995;1261-1267.
41. LaVecchio JA, Dunne AD, Edge AS. Enzymatic removal of alpha-galactosyl epitopes from porcine endothelial cells diminishes the cytotoxic effect of natural antibodies. Transplantation. 60:1995;841-847.
42. Hoopes CW, Platt JF. Molecular strategies for clinical xenotransplantation in cardiothoracic surgery. Semin Thorac Cardiovasc Surg. 8:1996;156-174.
43. Platt JL, Logan JS. Use of transgenic animals in xenotransplantation. Transplant Rev. 10:1996;69-77.
44. Cozzi E, White DJG. The generation of transgenic pigs as potential organ donors for humans. Nature Med. 1:1995;964-966.
45. Kroshus TJ, Bolman RM III, Dalmasso AP, et al. Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model. Transplantation. 61:1996;1513-1521.
46. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury. Nature Med. 1:1995;423-427.
47. Tearle RG, Tange MJ, Zannettino ZL, et al. The alpha-1,3 galactosyltransferase knockout mouse. Implications for xenotransplantation. Transplantation. 61:1996;13-19.
48. Kostecke RA, Ildstad ST. Chimerism and the facilitating cell. Transplant Rev. 9:1995;97-110.
49. Li H, Aboul El-Ezz AY, Gambrell BE, Ildstad ST. Mixed xenogeneic chimerism and tolerance III. Transplantation. 60:1995;59-65.
50. Ildstad ST, Wren SM, Sharrow SO, Stephany D, Sachs DH. In vivo and in vitro characterization of specific hyporeactivity to skin xenografts in mixed xenogeneically reconstituted mice (B10 + F344 rat → B10). J Exp Med. 160:1984;1820-1835.
51. Tomita Y, Lee LA, Sykes M. Engraftment of rat bone marrow and its role in negative selection of murine T cells in mice conditioned with a modified nonmyeloablative regimen. Xenotransplantation. 1:1994;109-117.
52. Li H, Ricordi C, Demetris AJ, et al. Mixed xenogeneic chimerism (mouse + rat → mouse) to induce donor-specific tolerance to sequential or simultaneous islet xenografts. Transplantation. 57:1994;592-598.
53. Zhao Y, Swenson K, Sergio JJ, Arn JS, Sachs DH, Sykes M. Skin graft tolerance across a discordant xenogeneic barrier. Nature Med. 2:1996;1211-1215.
54. Latinne D, Vitiello DM, Sachs DH, Sykes M. Tolerance to discordant xenografts. Transplantation. 57:1994;238-245.
55. Fox IJ, Athan E, Fisher J, Baxter T, Podda S, Richardson C. Use of gene therapy to induce human-mouse xenogeneic chimerism. Surgery. 114:1993;174-181.